Skip to main
MBOT
MBOT logo

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc. has developed the LIBERTY Endovascular Robotic System, which is anticipated to enhance procedure efficiency, lower costs, and improve overall care quality in endovascular procedures. The total addressable market for the company could grow from 2.5 million annual peripheral endovascular procedures in the U.S., contributing to an estimated market value of $843 million for the firm, supported by a discounted cash flow-based asset value of $781 million for the LIBERTY System. Additionally, the system's performance, evidenced by a remarkable 92% relative reduction in radiation exposure for operators, further underscores the technological advancement and potential for widespread adoption within the medical community.

Bears say

Microbot Medical faces significant risks that may hinder its financial performance, particularly slower than expected commercial uptake influenced by market size, penetration rates, and competition in the medical device sector. Additionally, there is a concern regarding potential dilution risk, which could affect shareholder value and investor confidence. These factors contribute to a challenging outlook for the company's stock, reflecting uncertainties in its market adoption and financial stability.

Microbot Medical (MBOT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.